Pivotal bioVenture Partners
VC Fund
San Francisco, United States
Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. They invest at all stages in a company’s evolution, from company creation through midand late stage clinical development. Their team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses.
- Total investments:
- 47
- Last investment:
- Lead investor:
- 30%
- Fund size:
- $300M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Pivotal bioVenture Partners invests in
Stages Pivotal bioVenture Partners invests in
Countries Pivotal bioVenture Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 23 (49%)
- Pharmaceutical 16 (34%)
- Health Care 15 (32%)
- Medical 9 (19%)
- Therapeutics 9 (19%)
Stage
- Series B 18 (38%)
- Series C 6 (13%)
- Series A 4 (9%)
- Seed 2 (4%)
- Series D 2 (4%)
Country
- United States 18 (38%)
- China 2 (4%)
- Canada 1 (2%)
- Iceland 1 (2%)
- Ireland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ash Khanna
Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune
|
Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune | Total investments: 6 | Find email | |
Heather Preston
Managing Partner
|
Managing Partner | Total investments: 11 | Find email | |
Jeni Lee
Partner
|
Partner | Total investments: 3 | Find email | |
Robert Hopfner
Managing Partner
|
Managing Partner | Total investments: 12 | Find email | |
|
Vincent Cheung
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Obsidian Therapeutics
|
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M / Post-IPO Equity / Aug 04, 2026 | |
Crystalys Therapeutics
|
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M / Series B / Jul 22, 2026 | |
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | |
LB Pharmaceuticals
|
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $100M / Post-IPO Equity / Feb 05, 2026 | |
NeuShen Therapeutics
|
NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders. | Series A / Jan 28, 2026 | |
Cybin
|
Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $175M / Post-IPO Equity / Oct 28, 2025 | |
Avalyn Pharma
|
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $100M / Series D / Jul 22, 2025 | |
Mosanna Therapeutics
|
Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. | $80M / Series A / Jun 09, 2025 | |
|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $200M / Series A / Jan 10, 2025 | |
Evommune
|
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $115M / Series C / Oct 31, 2024 | |
| See all 47 investments → | |||
Co-Investors
RA Capital Management
12 deals together
Novo Holdings
10 deals together
OrbiMed
8 deals together
Rock Springs Capital
8 deals together
SR One
8 deals together
Surveyor Capital
8 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Pivotal bioVenture Partners invest in?
Pivotal bioVenture Partners invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series C stage. Most of the 47 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pivotal bioVenture Partners?
Public channels for Pivotal bioVenture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pivotal bioVenture Partners?
The team at Pivotal bioVenture Partners includes Ash Khanna (Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune), Heather Preston (Managing Partner) and Jeni Lee (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
